AB0738 DUAL NEUTRALISATION OF INTERLEUKIN (IL)–17A AND IL–17F WITH BIMEKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: 60-WEEK RESULTS FROM A RANDOMISED, DOUBLE-BLINDED, PHASE 2B EXTENSION STUDY

Bimekizumab provides rapid and sustained improvements in scalp and nail outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized, double blinded, Phase 2b extension study

10.25251/skin.3.supp.34 ◽

2019 ◽

Vol 3 ◽

pp. S34

Author(s):

Andrew Blauvelt ◽

Kim A Papp ◽

Joseph F Merola ◽

Alice B Gottlieb ◽

Nancy Cross ◽

...

Keyword(s):

Plaque Psoriasis ◽

Extension Study ◽

Severe Plaque Psoriasis ◽

Abstract not available.

Bimekizumab provides rapid and sustained improvements in quality of life that correlate with clinical outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized , double blinded , Phase 2b extension study

10.25251/skin.3.supp.35 ◽

2019 ◽

Vol 3 ◽

pp. S35

Author(s):

Kim A Papp ◽

Joseph F Merola ◽

Alice B Gottlieb ◽

Christopher EM Griffiths ◽

Kristina K Harris ◽

...

Keyword(s):

Quality Of Life ◽

Clinical Outcomes ◽

Plaque Psoriasis ◽

Extension Study ◽

Severe Plaque Psoriasis ◽

Abstract not available.

Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study

10.1016/j.jaad.2020.05.105 ◽

2020 ◽

Vol 83 (5) ◽

pp. 1367-1374 ◽

Cited By ~ 3

Author(s):

Andrew Blauvelt ◽

Kim A. Papp ◽

Joseph F. Merola ◽

Alice B. Gottlieb ◽

Nancy Cross ◽

...

Keyword(s):

Plaque Psoriasis ◽

Extension Study ◽

Severe Plaque Psoriasis ◽

A Multi-Center, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study Evaluating Efficacy and Safety of Vunakizumab in Patients with Moderate-to-Severe Plaque Psoriasis

10.1016/j.jaad.2022.01.005 ◽

2022 ◽

Author(s):

Chunlei Zhang ◽

Kexiang Yan ◽

Qingchun Diao ◽

Qing Guo ◽

Hongzhong Jin ◽

...

Keyword(s):

Plaque Psoriasis ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Dose Ranging ◽

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial

British Journal of Dermatology ◽

10.1111/bjd.18851 ◽

2020 ◽

Vol 182 (6) ◽

pp. 1348-1358 ◽

Cited By ~ 18

Author(s):

A. Blauvelt ◽

K. Papp ◽

A. Gottlieb ◽

A. Jarell ◽

K. Reich ◽

...

Keyword(s):

Plaque Psoriasis ◽

Severe Plaque Psoriasis ◽

Speed Of Response ◽

Double Blinded ◽

Blinded Trial

25934 Bimekizumab efficacy for moderate to severe plaque psoriasis across patient subgroups: Pooled results from 3 multicenter, randomized, double-blinded phase 3 trials

10.1016/j.jaad.2021.06.329 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB76

Author(s):

Bruce Strober ◽

Richard B. Warren ◽

Peter Foley ◽

Melinda Gooderham ◽

Diamant Thaçi ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase 3 ◽

Severe Plaque Psoriasis ◽

Double Blinded ◽

Patient Subgroups

Five-year open-label extension study of safety and efficacy of etanercept in children and adolescents with moderate to severe plaque psoriasis

10.1016/j.jaad.2016.02.977 ◽

2016 ◽

Vol 74 (5) ◽

pp. AB251

Keyword(s):

Children And Adolescents ◽

Plaque Psoriasis ◽

Extension Study ◽

Open Label ◽

Safety And Efficacy ◽

Severe Plaque Psoriasis ◽

Open Label Extension

Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial

10.25251/skin.5.supp.53 ◽

2021 ◽

Vol 5 (6) ◽

pp. s53

Author(s):

Andrew Blauvelt ◽

Lars Iversen ◽

Sandy McBride ◽

Melinda Gooderham ◽

Petra Staubach ◽

...

Keyword(s):

Plaque Psoriasis ◽

Severe Plaque Psoriasis ◽

N/A

Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE)

10.25251/skin.5.supp.15 ◽

2021 ◽

Vol 5 (1) ◽

pp. s15

Author(s):

RB Warren ◽

A Blauvelt ◽

J Bagel ◽

KA Papp ◽

P Yamauchi ◽

...

Keyword(s):

Plaque Psoriasis ◽

Efficacy And Safety ◽

Phase 3 ◽

Active Comparator ◽

Severe Plaque Psoriasis ◽

Abstract not available.

Bimekizumab versus Ustekinumab Efficacy Across Subgroups of Patients with Moderate to Severe Plaque Psoriasis: Results from the Multicenter, Randomized, Double-Blinded Phase 3 BE VIVID Trial

10.25251/skin.5.supp.16 ◽

2021 ◽

Vol 5 (1) ◽

pp. s16

Author(s):

B Strober ◽

JG Krueger ◽

N Magnolo ◽

R Vender ◽

DP Toth ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase 3 ◽

Severe Plaque Psoriasis ◽

Abstract not available.